Virtual Cellは何を予測できたのか――標的遺伝子と評価指標の落とし穴
標的遺伝子の直接効果と摂動応答の予測を分け、最新研究と合成例からVirtual Cellの評価指標を点検する。
Daiki Kumakura
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
Recent writing
Nimotuzumabの実測PKから考える、曝露比較に必要なモデルの複雑さ
個人別PKから3つのPopPK構造を推定し、内部検証・収束・投与条件の曝露差からモデル採用の限界を検討する。
Does a tumor-kinetic model add anything to a single early tumor change?
At 16, 24 and 32 weeks, a mixed-effects tumor-kinetic estimate added no held-out survival discrimination beyond the observed one-point change, and carrying the last value forward predicted the next measurement best.